Suppr超能文献

P2Y₁₄受体荧光激动剂的设计、合成及药理学特性研究

Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor.

作者信息

Kiselev Evgeny, Balasubramanian Ramachandran, Uliassi Elisa, Brown Kyle A, Trujillo Kevin, Katritch Vsevolod, Hammes Eva, Stevens Raymond C, Harden T Kendall, Jacobson Kenneth A

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Department of Pharmacology, University of North Carolina, School of Medicine, Chapel Hill, NC 27599, USA.

出版信息

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4733-4739. doi: 10.1016/j.bmcl.2015.08.021. Epub 2015 Aug 10.

Abstract

The P2Y14R is a G(i/o)-coupled receptor of the P2Y family of purinergic receptors that is activated by extracellular UDP and UDP-glucose (UDPG). In an earlier report we described a P2Y14R fluorescent probe, MRS4174, based on the potent and selective antagonist PPTN, a naphthoic acid derivative. Here, we report the design, preparation, and activity of an agonist-based fluorescent probe MRS4183 (11) and a shorter P2Y14R agonist congener, which contain a UDP-glucuronic acid pharmacophore and BODIPY fluorophores conjugated through diaminoalkyl linkers. The design relied on both docking in a P2Y14R homology model and established structure activity relationship (SAR) of nucleotide analogs. 11 retained P2Y14R potency with EC50 value of 0.96 nM (inhibition of adenylyl cyclase), compared to parent UDPG (EC50 47 nM) and served as a tracer for microscopy and flow cytometry, displaying minimal nonspecific binding. Binding saturation analysis gave an apparent binding constant for 11 in whole cells of 21.4±1.1 nM, with a t1/2 of association at 50 nM 11 of 23.9 min. Known P2Y14R agonists and PPTN inhibited cell binding of 11 with the expected rank order of potency. The success in the identification of a new P2Y14R fluorescent agonist with low nonspecific binding illustrates the advantages of rational design based on recently determined GPCR X-ray structures. Such conjugates will be useful tools in expanding the SAR of this receptor, which still lacks chemical diversity in its collective ligands.

摘要

P2Y14R是嘌呤能受体P2Y家族中一种与G(i/o)偶联的受体,可被细胞外UDP和UDP-葡萄糖(UDPG)激活。在之前的一份报告中,我们描述了一种基于强效选择性拮抗剂PPTN(一种萘酸衍生物)的P2Y14R荧光探针MRS4174。在此,我们报告了一种基于激动剂的荧光探针MRS4183(11)和一种较短的P2Y14R激动剂同系物的设计、制备及活性,它们含有UDP-葡萄糖醛酸药效基团和通过二氨基烷基接头共轭的BODIPY荧光团。该设计既依赖于在P2Y14R同源模型中的对接,也依赖于已确立的核苷酸类似物结构活性关系(SAR)。与母体UDPG(EC50为47 nM)相比,11保留了P2Y14R活性,其EC50值为0.96 nM(抑制腺苷酸环化酶),并用作显微镜检查和流式细胞术的示踪剂,显示出最小的非特异性结合。结合饱和分析得出11在全细胞中的表观结合常数为21.4±1.1 nM,在50 nM 11时的缔合半衰期为23.9分钟。已知的P2Y14R激动剂和PPTN以预期的效力等级顺序抑制11与细胞的结合。成功鉴定出一种具有低非特异性结合的新型P2Y14R荧光激动剂,说明了基于最近确定的GPCR X射线结构进行合理设计的优势。此类共轭物将成为扩展该受体SAR的有用工具,该受体的总体配体仍缺乏化学多样性。

相似文献

1
Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor.
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4733-4739. doi: 10.1016/j.bmcl.2015.08.021. Epub 2015 Aug 10.
2
Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes.
ACS Chem Biol. 2014 Dec 19;9(12):2833-42. doi: 10.1021/cb500614p. Epub 2014 Oct 20.
3
Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands.
Bioorg Med Chem. 2015 Jul 15;23(14):4056-64. doi: 10.1016/j.bmc.2015.03.042. Epub 2015 Mar 21.
4
Recent progress on the discovery of P2Y receptor antagonists.
Eur J Med Chem. 2019 Aug 1;175:34-39. doi: 10.1016/j.ejmech.2019.04.068. Epub 2019 Apr 29.
5
Tools and drugs for uracil nucleotide-activated P2Y receptors.
Pharmacol Ther. 2018 Oct;190:24-80. doi: 10.1016/j.pharmthera.2018.04.002. Epub 2018 Apr 13.
6
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.
J Med Chem. 2016 Jul 14;59(13):6149-68. doi: 10.1021/acs.jmedchem.6b00044. Epub 2016 Jun 22.
7
Discovery of a series of novel 3-sulfonamido benzoic acid derivatives as promising P2YR antagonists for acute lung injury.
Eur J Med Chem. 2025 Jun 5;290:117588. doi: 10.1016/j.ejmech.2025.117588. Epub 2025 Apr 1.
8
UDP-sugars activate P2Y receptors to mediate vasoconstriction of the porcine coronary artery.
Vascul Pharmacol. 2018 Apr;103-105:36-46. doi: 10.1016/j.vph.2017.12.063. Epub 2017 Dec 15.
9
A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils.
Mol Pharmacol. 2013 Jul;84(1):41-9. doi: 10.1124/mol.113.085654. Epub 2013 Apr 16.
10
Structure-activity relationships of pyrimidine nucleotides containing a 5'-α,β-methylene diphosphonate at the P2Y receptor.
Bioorg Med Chem Lett. 2021 Aug 1;45:128137. doi: 10.1016/j.bmcl.2021.128137. Epub 2021 May 26.

引用本文的文献

1
Pharmacological characterization of P2Y receptor subtypes - an update.
Purinergic Signal. 2024 Apr;20(2):99-108. doi: 10.1007/s11302-023-09963-w. Epub 2023 Sep 12.
3
Molecular Modeling Applied to the Discovery of New Lead Compounds for P2 Receptors Based on Natural Sources.
Front Pharmacol. 2020 Sep 29;11:01221. doi: 10.3389/fphar.2020.01221. eCollection 2020.
4
Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.
ChemMedChem. 2020 Nov 4;15(21):1958-1973. doi: 10.1002/cmdc.202000465. Epub 2020 Sep 18.
5
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design.
Methods Mol Biol. 2018;1705:45-72. doi: 10.1007/978-1-4939-7465-8_3.
6
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.
J Med Chem. 2016 Jul 14;59(13):6149-68. doi: 10.1021/acs.jmedchem.6b00044. Epub 2016 Jun 22.
7
Medicinal chemistry of adenosine, P2Y and P2X receptors.
Neuropharmacology. 2016 May;104:31-49. doi: 10.1016/j.neuropharm.2015.12.001. Epub 2015 Dec 12.

本文引用的文献

2
Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands.
Bioorg Med Chem. 2015 Jul 15;23(14):4056-64. doi: 10.1016/j.bmc.2015.03.042. Epub 2015 Mar 21.
3
UDP-Sugars as Extracellular Signaling Molecules: Cellular and Physiologic Consequences of P2Y14 Receptor Activation.
Mol Pharmacol. 2015 Jul;88(1):151-60. doi: 10.1124/mol.115.098756. Epub 2015 Mar 31.
4
Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes.
ACS Chem Biol. 2014 Dec 19;9(12):2833-42. doi: 10.1021/cb500614p. Epub 2014 Oct 20.
5
The G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice.
J Biol Chem. 2014 Aug 22;289(34):23353-66. doi: 10.1074/jbc.M114.580803. Epub 2014 Jul 3.
6
Agonist-bound structure of the human P2Y12 receptor.
Nature. 2014 May 1;509(7498):119-22. doi: 10.1038/nature13288.
8
Structure of the human P2Y12 receptor in complex with an antithrombotic drug.
Nature. 2014 May 1;509(7498):115-8. doi: 10.1038/nature13083. Epub 2014 Mar 23.
9
The evolving small-molecule fluorescent-conjugate toolbox for Class A GPCRs.
Br J Pharmacol. 2014 Mar;171(5):1073-84. doi: 10.1111/bph.12265.
10
A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils.
Mol Pharmacol. 2013 Jul;84(1):41-9. doi: 10.1124/mol.113.085654. Epub 2013 Apr 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验